These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 30189807)

  • 41. Approvable generic carbamazepine formulations may not be bioequivalent in target patient populations.
    Tothfalusi L; Endrenyi L
    Int J Clin Pharmacol Ther; 2013 Jun; 51(6):525-8. PubMed ID: 23611573
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical, Pharmacokinetic, and In Vitro Studies to Support Bioequivalence of Ophthalmic Drug Products.
    Choi SH; Lionberger RA
    AAPS J; 2016 Jul; 18(4):1032-8. PubMed ID: 27184578
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Considerations concerning generic formulations of immunosuppressive drugs.
    Kahan BD
    Transplant Proc; 1999 May; 31(3):1635-41. PubMed ID: 10331031
    [No Abstract]   [Full Text] [Related]  

  • 44. [Trends in the quality evaluation of generic products and bioequivalence guidelines].
    Yomota C
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2012; (130):1-12. PubMed ID: 23243982
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Drug substitution in transplantation.
    Huang M; Wimberley S
    Am J Kidney Dis; 1999 Jul; 34(1):206. PubMed ID: 10428729
    [No Abstract]   [Full Text] [Related]  

  • 46. Applications of Adaptive Designs in Generic Drug Development.
    Lee J; Feng K; Xu M; Gong X; Sun W; Kim J; Zhang Z; Wang M; Fang L; Zhao L
    Clin Pharmacol Ther; 2021 Jul; 110(1):32-35. PubMed ID: 32940349
    [No Abstract]   [Full Text] [Related]  

  • 47. Bioequivalence study designs for generic solid oral anticancer drug products: scientific and regulatory considerations.
    Kaur P; Chaurasia CS; Davit BM; Conner DP
    J Clin Pharmacol; 2013 Dec; 53(12):1252-60. PubMed ID: 23996908
    [TBL] [Abstract][Full Text] [Related]  

  • 48. International veterinary bioequivalence guideline similarities and differences between Australia, Canada, Europe, Japan, New Zealand and the United States.
    Lainesse C
    AAPS J; 2012 Dec; 14(4):792-8. PubMed ID: 22864669
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Recommendations concerning the introduction of generic formulations of cyclosporine.
    Kahan BD
    Transplant Proc; 1999 May; 31(3):1634; discussion 1675-84. PubMed ID: 10331030
    [No Abstract]   [Full Text] [Related]  

  • 50. Model Informed Drug Development and Regulation in China: Challenges and Opportunities.
    Li L; Han H; Wang J; Wei C; Wang Y; Li M; Zhou Y; Yang J
    CPT Pharmacometrics Syst Pharmacol; 2019 Feb; 8(2):59-61. PubMed ID: 30407746
    [No Abstract]   [Full Text] [Related]  

  • 51. Generic-to-generic lamotrigine switches in people with epilepsy: the randomised controlled EQUIGEN trial.
    Privitera MD; Welty TE; Gidal BE; Diaz FJ; Krebill R; Szaflarski JP; Dworetzky BA; Pollard JR; Elder EJ; Jiang W; Jiang X; Berg M
    Lancet Neurol; 2016 Apr; 15(4):365-72. PubMed ID: 26875743
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Variability and impact on design of bioequivalence studies.
    Van Peer A
    Basic Clin Pharmacol Toxicol; 2010 Mar; 106(3):146-53. PubMed ID: 20041877
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Interchangeability of Generics-Experiences and Outlook Toward Pharmacokinetics Variability and Generic-Generic Substitution.
    Yu Y; Maliepaard M
    Clin Pharmacol Ther; 2019 Feb; 105(2):292-294. PubMed ID: 30460681
    [No Abstract]   [Full Text] [Related]  

  • 54. Bioequivalence studies for levothyroxine.
    Bolton S
    AAPS J; 2005 Mar; 7(1):E47-53. PubMed ID: 16146349
    [TBL] [Abstract][Full Text] [Related]  

  • 55. From antiretroviral originator to generic drugs: bioequivalence and pharmacovigilance.
    Bagheri H; Garraffo R; Dellamonica P
    Med Mal Infect; 2014 Oct; 44(10):464-9. PubMed ID: 25234382
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Generic drugs. Therapeutic equivalence.
    Meredith PA
    Drug Saf; 1996 Oct; 15(4):233-42. PubMed ID: 8905248
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Original and generic drugs: what does the clinician need to know?].
    Shchulkin AV; Filimonova AA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2021; 121(10. Vyp. 2):99-104. PubMed ID: 34870922
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Morality play.
    Eckert C
    Science; 1996 Sep; 273(5283):1784; author reply 1784-5. PubMed ID: 8815539
    [No Abstract]   [Full Text] [Related]  

  • 59. Acceptability of generic versus innovator oral medicines: not only a matter of taste.
    Tuleu C; Hughes DA; Clapham D; Vallet T; Ruiz F
    Drug Discov Today; 2021 Feb; 26(2):329-343. PubMed ID: 33217597
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Standard curve range for clinical sample analysis of oral bioavailability/bioequivalence studies: dilemma, introspection and strategies.
    Tripathi P; Patel H; Kulshrestha T; Srinivas NR
    Bioanalysis; 2018 May; 10(10):717-722. PubMed ID: 29771145
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.